Swiss pharmaceutical giant Novartis (SIX:NOVN) is navigating a critical period of new challenges, as the company sharpens its focus on innovative medicines while facing the looming threat of patent expirations on its blockbuster drugs. The strategic landscape for Novartis is thrown into sharp relief by the recent activities of its former subsidiaries, such as eye care firm Alcon (NYSE:ALC)—spun out in 2019—which just announced its own major acquisition.
While Alcon expands its portfolio by buying STAAR Surgical, Novartis is contending with a different set of pressures. The primary challenge is the impending patent cliff for some of its most successful products, most notably the heart failure drug Entresto. The potential arrival of generic competition for this multi-billion dollar revenue driver poses a significant headwind to the company’s growth profile.
Novartis’s response has been a deliberate and radical strategic pivot. Following the spin-off of Alcon, the company completed the separation of its generics and biosimilars unit, Sandoz, in 2023. This move finalized its transformation into a “pure-play” innovative medicines company, designed to concentrate its capital and R&D efforts on developing the next generation of high-value, patent-protected therapies.
The success of this strategy now hinges entirely on the strength and productivity of its drug pipeline. Novartis is heavily invested in cutting-edge therapeutic areas like oncology, cardiovascular disease, and advanced platforms such as radioligand therapy. The company has made several “bolt-on” acquisitions to bolster this pipeline, but investors remain keenly focused on whether these new assets can mature quickly enough to offset the inevitable revenue decline from older drugs losing exclusivity.
For investors, the central question is whether Novartis’s focused, high-risk, high-reward strategy will pay off, or if the competitive and patent pressures will prove too great a challenge for its emerging pipeline to overcome.
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is NOVN one of them
